InterMune To Discuss Pirfenidone With FDA
InterMune Inc. (Nasdaq: ITMN) will meet with the Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee to discuss the company's idiopathic pulmonary firbrosis treatment pirfenidone. Shares of the biotechnology company leaped $8.08 to $22.69.
